Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)-Reference-Cited by-同舟云学术

Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)

Published:2022-04-14 Issue:5 Volume:13 Page:1053-1071
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Aravind S. R.,Singh Kiran P.,Aquitania Grace,Mogylnytska Liliia,Zalevskaya Alsu G.,Matyjaszek-Matuszek Beata,Wernicke-Panten Karin,Nguyên-Pascal My-Liên,Pierre Suzanne,Rotthaeuser Baerbel,Kramer Daniel,Mukherjee Bhaswati^ORCID

Funder

Sanofi

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13300-022-01255-7.pdf

Reference32 articles.

1. Novo Nordisk: NovoLog Mix 70/30 insulin aspart protamine and insulin aspart injectable suspension 100 units/mL, NovoNordisk. Prescribing Information, revised: 4/2021. https://www.novo-pi.com/novologmix7030.pdf Accessed 3 Dec 2021.

2. European Medicines Agency: NovoMix 30 (30% insulin aspart and 70% insulin aspart protamine). Summary of product characteristics, updated 12 November 2020. https://www.ema.europa.eu/en/documents/product-information/novomix-epar-product-information_en.pdf Accessed 3 Dec 2021.

3. Liebl A, Prusty V, Valensi P, Yang W, Strojek K, Linjawi S. Ten years of experience with biphasic insulin aspart 30. from drug development to the latest clinical findings. Drugs. 2012;72:1495–1520.

4. Liebl A, Mohan V, Yang W, Strojek K, Linjawi S. 15 years of experience with biphasic insulin aspart 30 in type 2 diabetes. Drugs R D. 2018;18:27–39.

5. American Diabetes Association, Draznin B, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45:S125–S43.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Insulins, Biosimilars, and Insulin Therapy;Diabetes Technology & Therapeutics;2023-02-01

2. Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes;Indian Journal of Endocrinology and Metabolism;2022-07

3. Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin;Diabetes Therapy;2022-06-01